Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Escalada, J. (Javier) | - |
dc.creator | Halimi, S. (Serge) | - |
dc.creator | Senior, P.A. (Peter A.) | - |
dc.creator | Bonnemaire, M. (Mireille) | - |
dc.creator | Cali, A.M.G. (Anna M. G.) | - |
dc.creator | Melas-Melt, L. (Lydie) | - |
dc.creator | Karalliedde, J. (Janaka) | - |
dc.creator | Ritzel, R.A. (Robert A.) | - |
dc.date.accessioned | 2023-03-30T10:29:16Z | - |
dc.date.available | 2023-03-30T10:29:16Z | - |
dc.date.issued | 2018 | - |
dc.identifier.citation | Escalada, J. (Javier); Halimi, S. (Serge); Senior, P.A. (Peter A.); et al. "Glycaemic control and hypoglycaemia benefits with insulin glargine 300 U/mL extend to people with type 2 diabetes and mild-to-moderate renal impairment". Diabetes obesity and metabolism. 20 (12), 2018, 2860 - 2868 | es |
dc.identifier.issn | 1462-8902 | - |
dc.identifier.uri | https://hdl.handle.net/10171/65816 | - |
dc.description.abstract | Aim: To investigate the impact of renal function on the safety and efficacy of insulin glargine 300 U/mL (Gla-300) and insulin glargine 100 U/mL (Gla-100). Materials and Methods: A meta-analysis was performed using pooled 6-month data from the EDITION 1, 2 and 3 trials (N = 2496). Eligible participants, aged ≥18 years with a diagnosis of type 2 diabetes (T2DM), were randomized to receive once-daily evening injections of Gla-300 or Gla-100. Pooled results were assessed by two renal function subgroups: estimated glomerular filtration rate (eGFR) <60 and ≥60 mL/min/1.73 m2 . Results: The decrease in glycated haemoglobin (HbA1c) after 6 months and the proportion of individuals with T2DM achieving HbA1c targets were similar in the Gla-300 and Gla-100 groups, for both renal function subgroups. There was a reduced risk of nocturnal (12:00-5:59 AM) confirmed (≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycaemia with Gla-300 in both renal function subgroups (eGFR <60 mL/min/1.73 m2 : relative risk [RR] 0.76 [95% confidence interval {CI} 0.62-0.94] and eGFR ≥60 mL/min/1.73 m2 : RR 0.75 [95% CI 0.67-0.85]). For confirmed (≤70 mg/dL [≤3.9 mmol/L]) or severe hypoglycaemia at any time of day (24 hours) the hypoglycaemia risk was lower with Gla-300 vs Gla-100 in both the lower (RR 0.94 [95% CI 0.86-1.03]) and higher (RR 0.90 [95% CI 0.85-0.95]) eGFR subgroups. Conclusions: Gla-300 provided similar glycaemic control to Gla-100, while indicating a reduced overall risk of confirmed (≤3.9 and <3.0 mmol/L [≤70 and <54 mg/dL]) or severe hypoglycaemia, with no significant difference between renal function subgroups. | es_ES |
dc.description.sponsorship | Sanofi sponsored, designed and coordinated the clinical trials presented in this meta-analysis. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Wiley | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Basal insulin | es_ES |
dc.subject | Glycaemic control | es_ES |
dc.subject | Hypoglycaemia | es_ES |
dc.subject | Insulin analogues | es_ES |
dc.subject | Meta-analysis | es_ES |
dc.subject | Type 2 diabetes | es_ES |
dc.title | Glycaemic control and hypoglycaemia benefits with insulin glargine 300 U/mL extend to people with type 2 diabetes and mild-to-moderate renal impairment | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.description.note | This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. | es_ES |
dc.identifier.doi | 10.1111/dom.13470 | - |
dadun.citation.endingPage | 2868 | es_ES |
dadun.citation.number | 12 | es_ES |
dadun.citation.publicationName | Diabetes obesity and metabolism | es_ES |
dadun.citation.startingPage | 2860 | es_ES |
dadun.citation.volume | 20 | es_ES |
dc.identifier.pmid | 30003642 | - |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.